Product Overview
Tirzepatide is a synthetic research compound supplied by Arche Research as a lyophilized material for lawful laboratory, analytical, and non-clinical research. Multiple nominal quantities are available through the strength selector on this page.
Research Context
Tirzepatide (also known as LY3298176) has been examined in published preclinical and clinical research involving its activity as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Investigations have primarily focused on its pharmacokinetic profile, receptor binding affinity, and metabolic pathway interactions in clinical trial settings. The references provided below are included to identify relevant scientific literature and do not constitute product-use, medical, or administration guidance.
Research References
- Coskun T, et al. “LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity.” Molecular Metabolism. 2018;17:104-116. DOI: 10.1016/j.molmet.2018.06.001.
- Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” The New England Journal of Medicine. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038.
